Stroke recovery enhancing therapies: lessons from recent clinical trials

Rogalewski A, Schäbitz W-R (2022)
Neural Regeneration Research 17(4): 717-720.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Abstract / Bemerkung
Poststroke recovery processes include restoration or compensation of function, respectively functions initially lost or new functions acquired after an injury. Therapeutic interventions can enhance these processes and/or reduce processes impeding regeneration. Numerous experimental studies suggest great opportunities for such treatments, but the results from recent large clinical trials using neuromodulators such as dopamine and fluoxetine are disappointing. The reasons for this are manifold affecting forward translation of results from animals models into the human situation. This "translational road block" is defined by differences between animals and humans with regard to the genetic and epigenetic background, size and anatomy of the brain, cerebral vascular anatomy, immune system, as well as clinical function and behavior. Backward blockade includes the incompatible adaption of targets and outcomes in clinical trials with regard to prior preclinical findings. For example, the design of clinical recovery trials varies widely and was characterized by the selection of different clinical endpoints, the inclusion a broad spectrum of stroke subtypes and clinical syndromes as well as different time windows for treatment initiation after infarct onset. This review will discuss these aspects based on the results of the recent stroke recovery trials with the goal to contribute to the currently biggest unmet need in stroke research- the development of a recovery enhancing therapy that improves the functional outcome of a chronic stroke patient.
Stichworte
amphetamine; brain; chronic stroke; clinical trial; dopamine; fluoxetine; recovery; regeneration; serotonin reuptake inhibitor; translation
Erscheinungsjahr
2022
Zeitschriftentitel
Neural Regeneration Research
Band
17
Ausgabe
4
Seite(n)
717-720
ISSN
1673-5374
eISSN
1876-7958
Page URI
https://pub.uni-bielefeld.de/record/2961889

Zitieren

Rogalewski A, Schäbitz W-R. Stroke recovery enhancing therapies: lessons from recent clinical trials. Neural Regeneration Research . 2022;17(4):717-720.
Rogalewski, A., & Schäbitz, W. - R. (2022). Stroke recovery enhancing therapies: lessons from recent clinical trials. Neural Regeneration Research , 17(4), 717-720. https://doi.org/10.4103/1673-5374.314287
Rogalewski, Andreas, and Schäbitz, Wolf-Rüdiger. 2022. “Stroke recovery enhancing therapies: lessons from recent clinical trials”. Neural Regeneration Research 17 (4): 717-720.
Rogalewski, A., and Schäbitz, W. - R. (2022). Stroke recovery enhancing therapies: lessons from recent clinical trials. Neural Regeneration Research 17, 717-720.
Rogalewski, A., & Schäbitz, W.-R., 2022. Stroke recovery enhancing therapies: lessons from recent clinical trials. Neural Regeneration Research , 17(4), p 717-720.
A. Rogalewski and W.-R. Schäbitz, “Stroke recovery enhancing therapies: lessons from recent clinical trials”, Neural Regeneration Research , vol. 17, 2022, pp. 717-720.
Rogalewski, A., Schäbitz, W.-R.: Stroke recovery enhancing therapies: lessons from recent clinical trials. Neural Regeneration Research . 17, 717-720 (2022).
Rogalewski, Andreas, and Schäbitz, Wolf-Rüdiger. “Stroke recovery enhancing therapies: lessons from recent clinical trials”. Neural Regeneration Research 17.4 (2022): 717-720.

Link(s) zu Volltext(en)
Access Level
OA Open Access

Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

References

Daten bereitgestellt von Europe PubMed Central.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 34472456
PubMed | Europe PMC

Suchen in

Google Scholar